Plain-language summary

This Phase 1 trial is comparing anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) and GM-CSF against other options for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 1 US location.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) (DRUG): anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells | GM-CSF (DRUG): Hematopoietic agent that helps form white blood cells.

Drugs / treatments

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details